Refractory Hodgkin Lymphoma Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Refractory Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 2

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Refractory Non-Hodgkin LymphomaB-cell LymphomaRelapsed Non Hodgkin Lymphoma+2 more
Rita Assi24 enrolled2 locationsNCT06484920
Recruiting
Phase 1

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Advanced Solid TumorRefractory Hodgkin Lymphoma
FBD Biologics Limited50 enrolled6 locationsNCT06487624
Recruiting
Phase 2

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center33 enrolled1 locationNCT04871607
Recruiting
Phase 2

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin LymphomaRelapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center257 enrolled8 locationsNCT03618550
Recruiting
Phase 2Phase 3

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Hodgkin's Disease, Adult
Hospital Regional de Alta Especialidad del Bajio20 enrolled1 locationNCT05595447
Recruiting
Phase 1Phase 2

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT05896046